Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Aurobindo Pharma Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods available in Australia are of acceptable quality, safety, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework governing the supply, advertising, and control of therapeutic goods, encompassing medicines, medical devices, and blood and blood components. Enacted by the Australian Parliament, the Act aims to protect public health by ensuring that therapeutic goods are safe and effective for their intended use. The Act empowers the Therapeutic Goods Administration (TGA) to manage and regulate therapeutic goods within Australia, ensuring compliance with stringent standards and oversight to safeguard consumers. In the context of the recent consent granted under sections 14 and 14A of the Therapeutic Goods Act 1989, the TGA allowed Aurobindo Pharma Australia Pty Ltd to supply specific batches of its pharmaceutical products that did not conform to certain labelling requirements. This decision was made to address non-compliance with the advisory statements on medicine labels, which are crucial for informing consumers about potential risks and interactions. The consent granted is temporary, effective from 22 January 2016 to 30 June 2016, and applies only to the specified batches, ensuring that the public health risk remains minimal while the manufacturer rectifies the labelling issues.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a broad range of products including medicines, medical devices, blood and tissues, and therapeutic goods advertising. This Act applies to persons and entities involved in the supply, manufacture, or importation of therapeutic goods within the Australian jurisdiction, as well as to the conduct and transactions associated with these goods. The Act extends to the entire Commonwealth of Australia, thereby regulating therapeutic goods across all states and territories. The Act does not specify exclusions but does allow for exemptions and thresholds through subordinate instruments, which can define specific conditions under which certain goods or practices may be exempt from particular requirements. These subordinate instruments can further extend or restrict the application of the Act by detailing specific regulations and standards that need to be adhered to. The consent granted under sections 14 and 14A of the Act allows for temporary deviations from certain regulatory requirements, subject to specific conditions that ensure the safety and efficacy of the therapeutic goods supplied.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) primarily governs the regulation of therapeutic goods in Australia. Under sections 14 and 14A of the Act, a delegate of the Secretary of the Department of Health has the authority to consent to certain variations from regulatory standards, provided certain conditions are met. In this particular case, the delegate has consented to the supply of specific batches of therapeutic goods produced by Aurobindo Pharma Australia Pty Ltd, which do not conform to the labelling requirements stipulated in the Therapeutic Goods Order No. 69. Specifically, these batches of products—Aspirin enteric coated tablets 100mg blister pack, Ibuprofen & Codeine Phosphate film coated tablet, blister pack, and Paracetamol 500 MG & Codeine Phosphate 10 MG tablets blister pack—lack certain advisory statements on their labels as required by the Medicines Advisory Statements Specifications 2014. Entities governed by the Act, such as Aurobindo Pharma Australia Pty Ltd, are required to ensure that their products meet all stipulated regulatory standards unless specific consent has been granted by a delegate of the Secretary. This includes, but is not limited to, adhering to labelling requirements that ensure consumer safety and informed use. The consent granted under sections 14 and 14A of the Act is conditional, meaning that it is limited in scope and duration, and applies only to the specific batches of products listed. The consent is also contingent upon the use of previously approved labels for these products, which were submitted with the application. Failure to comply with the conditions of the consent, or with the regulatory standards set forth in the Act and its associated Orders, could lead to significant legal consequences. While the Act does not explicitly outline the specific penalties for non-compliance in this context, breaches of the Therapeutic Goods Act can generally result in both civil and criminal penalties. Civil penalties may include fines up to certain statutory maximums, while criminal penalties could involve imprisonment. The exact penalties would depend on the nature and severity of the breach, as well as any applicable case law and statutory provisions. Therefore, it is imperative for entities governed by the Act to adhere strictly to the terms of any consent granted and to the overarching regulatory framework.